Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy

Biostatistics

Volumn 15, Issue 2, 2014, Pages 251-265

  Gabriel, Erin E ^a   Gilbert, Peter B ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Case control study; Causal inference; Clinical trials; Principal stratification; Survival analysis; Treatment efficacy curve; Weibull model

Indexed keywords

BIOLOGICAL MARKER;

BIOASSAY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STANDARDS; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; ENDPOINT DETERMINATION; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896752566     PISSN: 14654644     EISSN: 14684357     Source Type: Journal    
DOI: 10.1093/biostatistics/kxt055     Document Type: Article

References (19)

1. DCCT/EDIC RESEARCH, GROUP. (2011). Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. The New England Journal of Medicine 365(25), 2366-2376
2. DUERR, A., HUANG, Y., BUCHBINDER, S., COOMBS, R. W., SANCHEZ, J., DEL RIO, C., CASAPIA, M., SANTIAGO, S., GILBERT, P. B., COREY, L., and others. (2012). Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step study). Journal of Infectious Diseases 206(2), 258-266
3. FOLLMANN, D. (2006). Augmented designs to assess immune response in vaccine trials. Biometrics 62(4), 1161-1169
4. FRANGAKIS, C. E. AND RUBIN, D. B. (2002). Principal stratification in causal inference. Biometrics 58(1), 21-29
5. GILBERT, P. B., GROVE, D., GABRIEL, E. E., HUANG, Y., GRAY, G., HAMMER, S. M., BUCHBINDER, S. P., KUBLIN, J., COREY, L. AND SELF, S. G. (2011). A sequential phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. Statistical Communications in Infectious Diseases 3(1) [Epub ahead of print].
6. GILBERT, P. B. AND HUDGENS, M. G. (2008). Evaluating candidate principal surrogate endpoints. Biometrics 64(4), 1146-1154.
7. GILBERT, P. B., QIN, L. AND SELF, S. G. (2008). Evaluating a surrogate endpoint at three levels, with application to vaccine development. Statistics in Medicine 27(23), 4758-4778
8. GRAMBSCH, P. M. AND THERNEAU, T. M. (1994). Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81(3), 515-526
9. HERN ÁN, M. (2010). The hazards of hazard ratios. Epidemiology 21(1), 13-15
10. HUANG, Y. AND GILBERT, P. B. (2011). Comparing biomarkers as principal surrogate endpoints. Biometrics 67(4), 1442-1451
11. HUANG, Y.,GILBERT, P. B. AND WOLFSON, J. (2013). Design and estimation for evaluating principal surrogate markers in vaccine trials. Biometrics 69(2), 301-309
12. JOFFE, M. M. AND GREENE, T. (2009). Related causal frameworks for surrogate outcomes. Biometrics 65(2), 530-538
13. LI, Y., TAYLOR, J. M. G. AND ELLIOTT, M. R. (2010). A Bayesian approach to surrogacy assessment using principal stratification in clinical trials. Biometrics 66(2), 523-531
14. PEPE, M. S. AND FLEMING, T. R. (1991). A nonparametric method for dealing with mismeasured covariate data. Journal of the American Statistical Association 86(413), 108-113
15. QIN, L., GILBERT, P. B., FOLLMANN, D. AND DONGFENG, L. (2008). Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model. Annals of Applied Statistics 2(1), 386-407
16. TAYLOR, J. M. G., WANG, Y. AND THIBAUT, R. (2005). Counterfactual links to the proportion of treatment effect explained by a surrogate marker. Biometrics 61(4), 1102-1111
17. WOLFSON, J. (2009). Statistical methods for identifying surrogate endpoints in vaccine trials [Doctor of Philosophy Dissertation]. University of Washington, Department of Biostatistics
18. WOLFSON, J. AND GILBERT, P. B. (2010). Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials. Biometrics 66(4), 1153-1161
19. ZIGLER, C. M. AND BELIN, T. R. (2012). A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint. Biometrics 68, 922-932.